2 results
Approved WMOCompleted
CORE PERIODPrimary:* Evaluate the safety and tolerability of up to 24 weeks of AG-348 administration in patients with pyruvate kinase deficiency (PK deficiency).Secondary:* Evaluate the pharmacokinetics (PK) of AG-348 and the metabolite AGI-8702.*…
Approved WMOPending
Primary objective of this study is to enhance insight in differences in elemental cardiovascular physiology between different levels of VA-ECMO support, by comparing pressure-volume loop derived parameters between 4.0-3.0-2.0-1.0-0.5 L/min…